AACR 2026 – Moderna touts first-line data
The IDO/PD-L1 project mRNA-4359 shows early hints in first-line melanoma.
Ominous signs for EGFR degraders
BeOne's degrader BG-60366 appears to have been discontinued.
Gilead edges further away from Arcus
The disclosure comes as another of Arcus's TIGIT trials flops.
Kelonia turns its ASH late-breaker into a buyout
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
AACR 2026 – a CCR8 reality check
Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
AACR 2026 – Qilu challenges Torl in Claudin6
The company’s conjugate QLS5132 has produced intriguing, but early results.
AACR 2026 – Circle’s focus narrows
First-in-human results prompt a biomarker-defined approach for CID-078.
